CLAIMS

1. Liposomal formulations comprising at least one active hydrophilic agent encapsulated in liposomes composed of at least one lipid bilayer formed by a mixture of at least one neutral saturated phospholipid and at least one charged saturated lipid.

2. Liposomal formulations according to claim 1, characterised in that the neutral saturated phospholipid is chosen from amongst derivatives of phosphatidylcholine and their combinations.

3. Liposomal formulations according to claim 2, characterised in that the derivative of phosphatidylcholine is chosen from amongst DSPC, DPPC and DMPC.

4. Liposomal formulations according to claim 1, characterised in that the negatively charged saturated lipid is chosen from amongst a group composed of derivatives of phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidic acid and their combinations.

5. Liposomal formulations according to claim 4, characterised in that the negatively charged saturated lipid is chosen from amongst DSPG, DPPG and PS.

6. Liposomal formulations according to claim 1, characterised in that the positively charged saturated lipid is SA.

7. Liposomal formulations according to claims 1 to 6, that can also contain at least one other lipid chosen from amongst sterols and derivatives, gangliosides and sphingomyelins.

8. Liposomal formulations according to claim 7, characterised in that the sterol is cholesterol.

9. Liposomal formulations according to claim 1 characterised in that the active hydrophilic agent is a drug.

10. Liposomal formulations according to claim 9, characterised in that the drug has low molecular weight.

11. Liposomal formulations according to claim 10, characterised in that the drug with low molecular weight is selected from amongst 5-fluorouracil, acyclovir, iododeoxyuridine, methotrexate and ciprofloxacin.

12. Liposomal formulations according to the previous claims, comprising 5-FU encapsulated in liposomes composed of DSPC:DSPG.

13. Liposomal formulations according to claims 1 to 11, comprising 5-FU encapsulated in liposomes composed of DSPC:PS.

14. Liposomal formulations according to claims 1 to 11, comprising ACV encapsulated in liposomes composed of DPPC:CHOL:DPPG.

15. Liposomal formulations according to claims 1 to 11, comprising ACV encapsulated in liposomes composed of DSPC:DSPG.

16. Liposomal formulations according to the previous claims, characterised in that the bilayer lipids have a neutral saturated PLs/charged saturated lipid molar ratio between 50/50 and 95/5.

17. Liposomal formulations according to claim 16, characterised in that the neutral saturated PLs/charged saturated lipid molar ratio is between 80/20 and 95/5.

18. Liposomal formulations according to the previous claims, characterised in that the active hydrophilic agent/lipids molar ratio is between 0.01/1 and 40/1.

19. Liposomal formulations according to claim 18, characterised in that active hydrophilic agent/ lipids molar ratio is between 0.1/1 and 2/1.

20. Liposomal formulations according to claims 12, 13, 18 and 19, characterised in that the 5-FU / lipid molar ratio is between 0.2 and 1.5.

21. Liposomal formulations according to claim 20, characterised in that the 5-FU/lipid molar ratio is between 0.5 and 1.0.

22. Pharmaceutical formulations that contain liposomal formulations according to any of claims 1 to 21 and a pharmaceutically acceptable vehicle.

23. Pharmaceutical formulations according to claim 22, for the topical administration of pharmaceutically active ingredients.

24. Use of the formulations according to any of claims 1 to 21, in the preparation of a drug for the prevention and/or treatment of diseases or disorders in humans or animals.

25. Use according to claim 24 in which the disease or disorder affects the skin and/or mucous.

26. Use according to claim 25 of a liposomal formulation of 5-FU according to claims 12, 13, 16, 17, 20 or 21 in the preparation of a topical drug for the prevention and/or treatment of hyperproliferative diseases or disorders in the skin and/or mucous.

27. Use according to claim 25 of a liposomal formulation of ACV according to any of claims 14 to 19 in the preparation of a topical drug for the prevention and/or treatment of infections caused by the herpes virus in the skin and/or mucous.

28. Preparation procedures of liposomal formulations according to claims 1 to 21 that includes:

- Dissolving the lipids in a mixture of organic solvents;
- Eliminating the solvents until forming a lipid film in the walls of the container;
- Hydrating the film by stirring it with an aqueous solution of the active ingredient;
- If desired, extract the liposomic suspension formed through filters to select the vesicular size;
- Subjecting the resulting suspension to diafiltration with a buffer solution;
- If desired, dilute the liposomic suspension with a buffer solution.